Best Seller

Human CXCL13/BLC/BCA-1 Antibody

R&D Systems | Catalog # AF801

R&D Systems

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human, Mouse, Primate - Macaca mulatta (Rhesus Macaque), Rabbit, Transgenic Mouse, Xenograft

Applications

Validated:

Immunohistochemistry, Western Blot, Neutralization, Dual RNAscope ISH-IHC Compatible

Cited:

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Neutralization, Immunocytochemistry, Bioassay

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
View all CXCL13/BLC/BCA-1 Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human CXCL13/BCA-1
Val23-Arg94
Accession # Q53X90

Specificity

Detects CXCL13/BLC/BCA‑1 in direct ELISAs and Western blots. 

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human CXCL13/BLC/BCA-1 Antibody

Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody.

Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody.

Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin. Chemotaxis elicited by Recombinant Human CXCL13/BLC/BCA-1 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801). The ND50 is typically 1-4 µg/mL.
CXCL13/BLC/BCA-1 antibody in Human Lymphoma by Immunohistochemistry (IHC-P).

CXCL13/BLC/BCA‑1 in Human Lymphoma.

CXCL13/BLC/BCA-1 was detected in immersion fixed paraffin-embedded sections of human lymphoma using Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of CXCL13/BLC/BCA‑1 in Human Lymphoma.

Formalin-fixed paraffin-embedded tissue sections of Hodgkin’s Lymphoma were probed for CXCL13 mRNA (ACD RNAScope Probe, catalog # 311321; Fast Red chromogen, ACD catalog # 322360). Adjacent tissue section was processed for immunohistochemistry using goat anti-human CXCL13 polyclonal antibody (R&D Systems catalog # AF801) at 5ug/mL with 1-hour incubation at room temperature followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm.
Detection of CXCL13/BLC/BCA-1 by Flow Cytometry

Detection of CXCL13/BLC/BCA-1 by Flow Cytometry

The anti-tumor function of Tfh cells was impaired in PDAC. (A) Representative flow cytometry data and the proportion of functional cTfh cells (CXCL13+ IL-21+) from the peripheral blood of healthy donors (n = 4) and patients with PDAC of different stages (nI = 5, nII = 4, nIII = 4). (B) Representative flow cytometry data and (C) the proportion of CD8+ T cells and B cells recruited to the bottom of the Transwell chamber by cTfh cells treated with or without rhCXCL13 or anti-CXCL13 neutralizing antibodies. (D) Representative flow cytometry data and the proportion of plasma cells (CD27+ CD38+) in B cells (CD19+ CD20+) from the peripheral blood of healthy donors (n = 4) and patients with PDAC at different stages (nI = 5, nII = 4, nIII = 4). (E) Representative flow cytometry data and the proportion of IgG-secreting plasma cells from cells in (D). (F) Representative flow cytometry data and the proportion of IgM-secreting plasma cells from cells in (D). (G) Representative flow cytometry data and the proportion of plasma cells (CD27+ CD38+) in B cells (CD19+ CD20+) co-cultured with cTfh cells sorted from the peripheral blood of healthy donors (n = 3) and patients with PDAC (n = 3). (H) Representative flow cytometry data and the proportion of IgG-secreting plasma cells from cells in (G). (I) Representative flow cytometry data and the proportion of IgM-secreting plasma cells from cells in (G). Asterisks indicated the significance level of the p-value (* p < 0.05 and ** p < 0.01). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34359579), licensed under a CC-BY license. Not internally tested by R&D Systems.
Human CXCL13 / BLC / BCA-1 ELISA Standard Curve

Human CXCL13 / BLC / BCA-1 ELISA Standard Curve

Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801-CX) was serially diluted and captured by Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB801) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human CXCL13/BLC/BCA‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)

Applications for Human CXCL13/BLC/BCA-1 Antibody

Application
Recommended Usage

Dual RNAscope ISH-IHC Compatible

5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human lymphoma

Immunohistochemistry

5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human tonsil and human lymphoma

Western Blot

0.1 µg/mL
Sample: Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801-CX)

Neutralization

Measured by its ability to neutralize CXCL13/BLC/BCA‑1-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR5. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 50 ng/mL Recombinant Human CXCL13/BLC/BCA‑1.

Reviewed Applications

Read 7 reviews rated 4.6 using AF801 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.<br/>*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CXCL13/BLC/BCA-1

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23‑34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

References

  1. Gunn, M.D. et al. (1998) Nature, 391:799.
  2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
  3. Forster, R. et al. (1996) Cell 87:1037.

Alternate Names

ANGIE2, BCA-1, BCA1, BLC, BLR1L, SCYB13

Entrez Gene IDs

10563 (Human); 55985 (Mouse)

Gene Symbol

CXCL13

UniProt

Q53X90

Additional CXCL13/BLC/BCA-1 Products

Product Documents for Human CXCL13/BLC/BCA-1 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human CXCL13/BLC/BCA-1 Antibody

For research use only

Citations for Human CXCL13/BLC/BCA-1 Antibody

Customer Reviews for Human CXCL13/BLC/BCA-1 Antibody (7)

4.6 out of 5
7 Customer Ratings
5 Stars
57%
4 Stars
43%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Human CXCL13/BLC/BCA-1 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 5 of 7 reviews Showing All
Filter By:
Clear Filters X
  • Human CXCL13/BLC/BCA-1 Antibody
    Name: Yannick Alexandre
    Application: Flow Cytometry
    Sample Tested: Splenocytes
    Species: Human
    Verified Customer | Posted 07/06/2022
    CXCL13 and negative control.
    Human CXCL13/BLC/BCA-1 Antibody AF801
  • Human CXCL13/BLC/BCA-1 Antibody
    Name: Yannick Alexandre
    Application: Immunocytochemistry/Immunofluorescence
    Sample Tested: Spleen tissue
    Species: Human
    Verified Customer | Posted 07/06/2022
    Human spleens fixed in 4% PFA
    Human CXCL13/BLC/BCA-1 Antibody AF801
  • Human CXCL13/BLC/BCA-1 Antibody
    Name: Anonymous
    Application: Immunohistochemistry
    Sample Tested: Tonsil tissue
    Species: Human
    Verified Customer | Posted 12/10/2021
    Tonsil FFPE section. Primary Ab: 2ug/mL Detected using BOND Refine kit Rabbit anti-goat was used as Post Primary ER2 retrieval
    Human CXCL13/BLC/BCA-1 Antibody AF801
  • Human CXCL13/BLC/BCA-1 Antibody
    Name: Anonymous
    Application: Immunofluorescence - paraffin
    Sample Tested: Diffuse large B cell lymphoma
    Species: Human
    Verified Customer | Posted 01/16/2020
    anti-CXCL13 on DLBCL, 1:200 dilution
    pH 9 antigen retrieval
    Human CXCL13/BLC/BCA-1 Antibody AF801
  • Human CXCL13/BLC/BCA-1 Antibody
    Name: Chi P
    Application: Immunohistochemistry
    Sample Tested: Lymph node tissue
    Species: Rhesus Macaque
    Verified Customer | Posted 04/23/2018
    The CXCL13 can be observed in blue while CXCR5+ cells are observed in red
    Human CXCL13/BLC/BCA-1 Antibody AF801
  • Human CXCL13/BLC/BCA-1 Antibody
    Name: Anonymous
    Application: Immunohistochemistry
    Sample Tested: Spleen tissue
    Species: Rhesus Macaque
    Verified Customer | Posted 03/21/2018
  • Name: Anonymous
    Application: Immunohistochemistry-Paraffin
    Sample Tested: See PMID 23778140
    Species: Human
    Verified Customer | Posted 01/09/2015

There are no reviews that match your criteria.

Showing  1 - 5 of 7 reviews Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies